# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid syntha...
Goldman Sachs analyst Andrea Tan maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and lowers the price target from $27...
HC Wainwright & Co. analyst Ed Arce reiterates Sagimet Biosciences (NASDAQ:SGMT) with a Buy and maintains $32 price target.
Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid syntha...
Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid syntha...
HC Wainwright & Co. analyst Ed Arce initiates coverage on Sagimet Biosciences (NASDAQ:SGMT) with a Buy rating and announ...
Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid syntha...
Goldman Sachs analyst Andrea Tan maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and lowers the price target from $37...